drugset
drugset / Trial / NCT07704515

GKL-006Allo Injection in Patients With Advanced Solid Tumors

NCT07704515 ↗

Phase 1 Not yet recruiting 27 enrolled Beijing Gene Key Life Technology Co., Ltd
NaSequentialOpen-labelTreatment

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.

Timeline

Start
2026-08-30
Primary completion
2028-09-30
Completion
2029-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GKL-006Allo Injection Cell therapy — —

Indications

No indication recorded.